Forbes.com: Richmond, Calif.-based Sangamo Biosciences announced after the close on Monday that data from one of three midstage trials for the company's drug candidate SB-509 failed to deliver. The drug, which is meant to treat the lower-leg nerve damage caused by diabetes, showed no more improvement in patients than the placebo. It proved, however, to be safe and well-tolerated during repeat dosing.
And with that, my Plan B, namely to stay at Sangamo if I don't get in to med school, went up in a giant fireball. I have the utmost confidence in the power of zinc-finger technology; however, with the market as it is and with the failure of SB-509-601, the company will not be hiring interns to research assistant positions anytime soon. And lets not talk about the possible layoffs that loom large on everyone's mind...
No comments:
Post a Comment